

# Sector Vector Newsletter Promotional Opportunities



## Key Metrics

\*Average of issues Jan-Dec 2023



**18,000+**  
subscribers



**33%**  
average open rate\*




**8.5%**  
average click rates\*




**25%+**  
recipients are executive  
leaders

Executive Leadership  
(Common titles: CEO, COO, VP)



## Audiences



## PLACEMENT OPTIONS

### ▶ Banner Placement – Top

Hyperlinked banner and summary description (25 words or less).

Placement Bundles (subject to availability):



### ▶ Banner Placement – Middle

Hyperlinked banner

Placement Bundles (subject to availability):



### ▶ Banner Placement – End

Hyperlinked banner

Placement Bundles (subject to availability):



### ▶ Job Postings (Maximum 8 weeks)

Member Rate: → **\$150**  
per job posting per week

Non-Member Rate: → **\$200**  
per job posting per week

# AD PLACEMENTS

[View this email in your browser](#)

**THE SECTOR VECTOR**

*Delivering the latest news in gene therapy, cell therapy, & tissue engineering*

May 15, 2024



Join the **World's Largest Orphan Drug and Rare Disease Event** as we cover the start-to-finish of orphan drugs, from regulation and policy to global pricing and gene therapy.

**Business**

Bluebird bio announces first patient's cells collected for LYFGENIA and that 14 patient starts were completed for ZWTEGLO and SKYSONA since the beginning of 2024 - May 9

Iovance Biotherapeutics Updates That More Than 100 Patients Have Enrolled for Its Amtagvi Cell Therapy Since FDA Approval - May 9

Dyno Therapeutics to Accelerate Design of High-Performance Biological Sequences Using NVIDIA AI - May 9

Arbor Biotechnologies Announces Acquisition of Serendipity - May 8

Astellas Unveils New, State-of-the-Art, \$90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor - May 8

Caring Cross and ImmunoAdoptive Cell Therapy (ImmunoACT) Announce Agreement to Commercialize TrICAR-T Cell Immunotherapy for Leukemia and Lymphoma - May 7

**Top banner  
ad placement**

**CELL AND GENE** Register for your free weekly newsletter

**Manufacturing**

Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer - May 8

Donaldson Announces Integrated Lentiviral Vector Manufacturing Platform Development - May 8

Cellipoint Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform - May 7

WACKER Expands Production Capacity for Biopharmaceuticals in San Diego - May 6

Takara Bio launches first commercial dissolvable microfluidic lentiviral transduction enhancer - May 6

**Middle banner  
ad placement**

**INCLUSION** Diversity, Equity & Inclusion Summit. Tackle challenges in diversity, equity, and inclusion with leaders in life sciences. REGISTER NOW

**Clinical & Scientific**

Bloomsbury Genetic Therapies Showcases its First Preclinical Data on Parkinson's Disease Program - May 9

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting - May 9

Kate Therapeutics Presented Key Advances in Next-Generation DMD Gene Therapy - May 9

Poseida Therapeutics Highlights Strong Progress on Its Genetic Medicine Programs at the ASGCT 27th Annual Meeting - May 9

Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program - May 9

Eptor Therapeutics Unveils CasNano: A Compact, All-in-One CRISPR/Cas for Single AAV Therapies at the American Society of Gene & Cell Therapy Annual Meeting - May 9

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing - May 9

**Expedited Approval & Orphan Designations**

**CBER Cures Vacancy Announcement – Physician**  
AD-0602-Band C, Office of Therapeutic Products (OTP)

**Bottom banner  
ad placement**

**Sector Jobs**

**CBER Cures Vacancy Announcement – Physician**  
AD-0602-Band C, Office of Therapeutic Products (OTP)

**Job placement**